Advicenne SA logo

ADVIC - Advicenne SA Share Price

€7.02 -0.0  -0.6%

Last Trade - 07/08/20

Small Cap
Market Cap £53.3m
Enterprise Value £39.4m
Revenue £1.50m
Position in Universe 557th / 852
Unlock ADVIC Revenue
Relative Strength (%)
1m +4.36%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -45.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.11 0.27 0.56 0.96 1.66 12.5 11.7 +97.6%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Advicenne SA revenues increased 73% to EUR1.7M. Net loss increased from EUR5M to EUR14.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects European Union segment loss increase from EUR5.3M to EUR14.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.62 to -EUR1.74.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ADVIC Revenue Unlock ADVIC Revenue

Net Income

ADVIC Net Income Unlock ADVIC Revenue

Normalised EPS

ADVIC Normalised EPS Unlock ADVIC Revenue

PE Ratio Range

ADVIC PE Ratio Range Unlock ADVIC Revenue

Dividend Yield Range

ADVIC Dividend Yield Range Unlock ADVIC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADVIC EPS Forecasts Unlock ADVIC Revenue
Profile Summary

ADVICENNE S.A. is a late-stage biopharmaceutical company based in France. The Company focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated March 29, 2007
Public Since December 6, 2017
No. of Shareholders: n/a
No. of Employees: 32
Sector Healthcare
Industry Pharmaceuticals
Index CAC Mid & Small , CAC Small , CAC All-tradable , Enternext Pea-pme 150 ,
Exchange Euronext - Paris
Shares in Issue 8,413,644
Free Float (0.0%)
Eligible for
ADVIC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ADVIC
Upcoming Events for ADVIC
Frequently Asked Questions for Advicenne SA
What is the Advicenne SA share price?

As of 07/08/20, shares in Advicenne SA are trading at €7.02, giving the company a market capitalisation of £53.3m. This share price information is delayed by 15 minutes.

How has the Advicenne SA share price performed this year?

Shares in Advicenne SA are currently trading at €7.02 and the price has moved by -44.72% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Advicenne SA price has moved by -42.52% over the past year.

What are the analyst and broker recommendations for Advicenne SA?

Of the analysts with advisory recommendations for Advicenne SA, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Advicenne SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Advicenne SA next release its financial results?

Advicenne SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Advicenne SA dividend yield?

Advicenne SA does not currently pay a dividend.

Does Advicenne SA pay a dividend?

Advicenne SA does not currently pay a dividend.

When does Advicenne SA next pay dividends?

Advicenne SA does not currently pay a dividend.

How do I buy Advicenne SA shares?

To buy shares in Advicenne SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Advicenne SA?

Shares in Advicenne SA are currently trading at €7.02, giving the company a market capitalisation of £53.3m.

Where are Advicenne SA shares listed? Where are Advicenne SA shares listed?

Here are the trading details for Advicenne SA:

Country of listing: France
Exchange: PAR
Ticker Symbol: ADVIC
What kind of share is Advicenne SA?

Based on an overall assessment of its quality, value and momentum, Advicenne SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Advicenne SA share price forecast 2020?

Shares in Advicenne SA are currently priced at €7.02. At that level they are trading at 0.231% discount to the analyst consensus target price of 0.00.

Analysts covering Advicenne SA currently have a consensus Earnings Per Share (EPS) forecast of -1.68 for the next financial year.

How can I tell whether the Advicenne SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advicenne SA. Over the past six months, the relative strength of its shares against the market has been -16.69%. At the current price of €7.02, shares in Advicenne SA are trading at -17.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Advicenne SA PE Ratio?

We were not able to find PE ratio data for Advicenne SA.

Who are the key directors of Advicenne SA?

We were unable to find the directors for Advicenne SA.

Who are the major shareholders of Advicenne SA?

Here are the top five shareholders of Advicenne SA based on the size of their shareholding:

Bpifrance Investissement Venture Capital
Percentage owned: 27.81% (2.25m shares)
iXO Private Equity Private Equity
Percentage owned: 17.38% (1.41m shares)
Cemag Invest Corporation
Percentage owned: 9.1% (736k shares)
Humblet (Marie-Odile) Individual Investor
Percentage owned: 7.1% (574k shares)
IRDI SORIDEC Gestion Corporation
Percentage owned: 5.18% (419k shares)
Similar to ADVIC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.